Kiora Pharmaceuticals to Webcast On-Demand Presentation at The H.C. Wainwright 27th Annual Global Investment Conference
Encinitas, California--(Newsfile Corp. - September 4, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that its Chief Financial Officer, Melissa Tosca, CPA, will showcase the Company's pipeline of therapies targeting inherited and inflammatory retinal diseases at the H.C. Wainwright 27th Annual Global Investment Conference. Presentation Details
Biotechnology, Pharmaceuticals
2025-09-04 7:00 AM EDT | Kiora Pharmaceuticals, Inc.
Howie's 17+ Years After VesCell(TM): Following Hemostemix's Heart Patients
Calgary, Alberta--(Newsfile Corp. - September 3, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, in Florida under Florida's SB 1768, celebrated the 17+ ye
Biotechnology, Pharmaceuticals, Health
2025-09-03 8:47 AM EDT | Hemostemix Inc.
Phio Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference
King of Prussia, Pennsylvania--(Newsfile Corp. - September 3, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biopharmaceutical company developing therapeutics using its proprietary INTASYL® siRNA gene silencing technology to eliminate cancer. Phio today announced th
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-09-03 7:45 AM EDT | Phio Pharmaceuticals Corp.
Optimi Health Announces Launch of Psilocybin Capsules in Australia for Treatment-Resistant Depression
Vancouver, British Columbia--(Newsfile Corp. - September 3, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian manufacturer of GMP psychedelic medicines, is pleased to announce the commercial launch of its natural psilocybin capsules in Australia, which are now being prescribed to patients with Treatment-Resistant Depression ("TRD") under the Authorised Prescriber Scheme. The initial shipment of 1,000 psilocybin capsules, each conta
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-09-03 7:30 AM EDT | Optimi Health Corp.
TempraMed Closes Oversubscribed C$7.4M Financing and Advances Toward Go Public Listing
Sammamish, Washington--(Newsfile Corp. - September 3, 2025) - TempraMed Ltd. ("TempraMed" or the "Company"), a medical technology innovator redefining how temperature-sensitive medications are stored, managed and protected, is pleased to announce significant corporate and capital markets milestones, including the successful close of an oversubscribed C$7.4 million private placement financing and strong progress toward its public listing on the Canadian Securities Exchange (CSE), expected mid-
Technology, Biotechnology, Pharmaceuticals, Health
2025-09-03 7:00 AM EDT | TempraMed Technologies Ltd.